Dear Healthcare Professional,
This is a Letter on the introduction of Firstvue HBsAg Rapid Diagnostic Test for Hepatitis B Virus Surface Antigen. Firstvue brand a recognized leader in IVD Diagnostic’s is committed to improving public health worldwide, including fighting infectious diseases and viruses within the body. Firstvue vision for rapid diagnostic tests, that concentrate the company’s know-how in real world testing dynamics, and in meeting high quality standards.
Firstvue HBsAG Rapid 25 Pack Test Kit and USAMMCE
“Walter Reed’s Evaluation of FirstVue HBSAG Laboratory Evaluation of Hepatitis B Rapid Tests for Use in Screening Walking Blood bank Donors: A Walter Reed Evaluation Concluded That The Firstvue™ HBSAG Test is Preferred Over any Other Rapid Hepatitis B Tests…”
⦁ Summary: Firstvue One Step Hepatitis B Surface Antigen (HBsAg) Test is a rapid and convenient immunochromatographic assay for the qualitative detection of HBsAg in human whole blood, serum or plasma samples at or above a level of 1 ng/ml. It is intended for professional use as an aid in the diagnosis of Hepatitis B virus (HBV) infection. Further recommendations
Out of 40 manufactures, six rapid tests were initially selected from the rapid
HBSAG tests available worldwide, based on an evaluation of published claims and sensitivity testing using HBSAG positive samples. The tests were then compared in a comprehensive evaluation of test performance using plasma and blood specimens. The study indicated that the Firstvue™ HBSAG test had the highest sensitivity (95.4%) and the highest specificity (99.7%) among the tests evaluated. In addition, the evaluation indicated that the Firstvue™ HBSAG test detected HBSAG antibodies approximately three days sooner than available laboratory-based enzyme immunoassays and approximately sixteen days earlier than the next most sensitive rapid HBSAG test. Early detection of seroconversion is an important measure of the sensitivity of a test and means that hepatitis B infection can be identified even with relatively recent exposure.
** The study was conducted at The Walter Reed Army Institute of Research and involved investigators from the Walter Reed Army Institute of Research Division of Retrovirology, The U.S. Military HIV Research Program, Walter Reed Army Institute of Research Division of Military Casualty Research, the U.S. Army Blood Program, the Army Medical Department Center and School, the Robertson Blood Center and the American Red Cross. Conference information may be obtained at https://www.usaccc.org/ATACCC/index.htm